Criteria to select molecular targets for anti-fibrotic therapy

Rheumatology

Volumn 47, Issue SUPPL. 5, 2009, Pages

  Distler, J H W ^a   Distler, Oliver ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Fibroblasts; Fibrosis; Molecular therapies; Systemic sclerosis; Tyrosine kinase inhibitors

Indexed keywords

ABELSON KINASE; ADENOSINE A2A RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA;

CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

EID: 69949186412     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken277     Document Type: Conference Paper

References (10)

1. Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
2. Distler JH, Jungel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
3. Skhirtladze C, Distler O, Dees C et al. Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008;58:1475-84.
4. Akhmetshina A, Dees C, Pileckyte M et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2008, in press.
5. Huber LC, Distler JH, Moritz F et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007;56:2755-64.
6. Distler O, Pap T, Kowal-Bielecka O et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78.
7. Chan ES, Fernandez P, Merchant AA et al. Adenosine a2a receptors in diffuse dermal fibrosis: Pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006;54:2632-42.
8. Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 2006;20:562-4.
9. White B, Bauer EA, Goldsmith LA et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995;38:351-60.
10. Gardner H, Shearstone JR, Bandaru R et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006;54:1961-73.